Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lipocine Inc LPCN

Healthcare
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor... see more

Recent & Breaking News (NDAQ:LPCN)

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Lipocine Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Business Wire November 15, 2019

Pomerantz Law Firm Announces the Filing of a Class Action against Lipocine Inc. and Certain Officers - LPCN

GlobeNewswire November 15, 2019

EQUITY ALERT: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Lipocine Inc. - LPCN

Business Wire November 15, 2019

Lipocine Announces Pricing Of Public Offering Of Common Stock And Warrants

PR Newswire November 14, 2019

Lipocine Announces Launch Of Public Offering Of Common Stock And Warrants

PR Newswire November 13, 2019

Lipocine Announces Third Quarter 2019 Financial and Operational Results

PR Newswire November 12, 2019

LPCN LOSSES ALERT: Bernstein Liebhard LLP Reminds Investors of Its Investigation of Lipocine Inc

ACCESSWIRE IA November 11, 2019

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Lipocine Inc. (LPCN)

ACCESSWIRE IA November 11, 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Lipocine Inc. - LPCN

GlobeNewswire November 11, 2019

Lipocine Receives Complete Response Letter for TLANDO(TM) from U.S. FDA

PR Newswire November 11, 2019

Lipocine to Present at the B. Riley NASH Symposium

PR Newswire October 14, 2019

Lipocine to Present at the H.C. Wainwright 3rd Annual NASH Investor Conference

PR Newswire October 10, 2019

Lipocine To Present LPCN 1144 Poster Of Distinction At The Liver Meeting® 2019

PR Newswire October 1, 2019

First Biopsy Confirmed Nash Patient Dosed In Lipocine LiFT Study Of LPCN 1144

PR Newswire September 30, 2019

Lipocine Announces Presentations at the 20th Annual Fall Meeting of the Sexual Medicine Society of North America

PR Newswire September 23, 2019

Lipocine to Participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma, Rare Disease & Gene Therapy

PR Newswire September 16, 2019

Lipocine Announces Trial Date in Lipocine's Infringement Lawsuit Against Clarus Therapeutics and Will Seek a Permanent Injunction

PR Newswire August 27, 2019

Lipocine Announces Second Quarter 2019 Financial and Operational Results

PR Newswire August 7, 2019

Lipocine to Present at the Canaccord Genuity 39th Annual Growth Conference

PR Newswire July 30, 2019

Lipocine Receives FDA Clearance for Clinical Testing its NASH Candidate, LPCN 1144, in Expanded Target Population

PR Newswire July 23, 2019